Searching journal content for endocrine treatment (as phrase) in full text.

Displaying results 1-10 of 136
For checked items
  1. ...endocrine treatment resistant breast cancers. BMPs and progression of breast cancer BMPs in epithelial–mesenchymal transition (EMT) EMT is an important event during the development and progression of cancer, causing disruption of epithelial homeostasis that may lead to carcinogenesis; it can also tr ~~~
  2. ...endocrine treatment for PCa leads to global sex steroid deprivation. The ensuing severe hypogonadism is associated with well-documented adverse effects. Recently, it has become apparent that many of the biological actions attributed to androgens in men are in fact not direct, but mediated by estradi ~~~
  3. ...endocrine treatment Introduction Male breast cancer is rare, accounting for around 1% of all breast cancers ( Siegel et al. 2016 ) and is frequently positive for ERα (91–95%) and/or PR (80–81%) ( Giordano et al. 2004 , Anderson et al. 2010 , Nilsson et al. 2013 ). The most well-known anti-estrogenic ~~~
  4. ...endocrine treatment is an obstacle in treating ER-positive/AR-positive BC. Preclinical data have shown that AR overexpression may induce tamoxifen resistance (Peters et al. 2009) and that antagonism of AR may restore tamoxifen sensitivity by inhibiting the ER agonist response of tamoxifen (De Amicis ~~~
  5. ...endocrine treatment has been proposed as an alternative to long-term neoadjuvant therapy to assess tumor response (Dowsett et  al. 2007). In addition, low doses of TAM have been proposed for chemoprevention in women at high risk of developing breast cancer (Lazzeroni et  al. 2012). Hypersensitivity ~~~
  6. ...endocrine treatment . Journal of Clinical Oncology 20 3396 – 3403 . ( doi:10.1200/JCO.2002.10.057 ) ↵ Jeselsohn R , Yelensky R , Buchwalter G , Frampton G , Meric-Bernstam F , Gonzalez-Angulo AM , Ferrer-Lozano J , Perez-Fidalgo JA , Cristofanilli M , Gomez H et al. 2014 Emergence of constitutively ~~~
  7. ...endocrine treatment of endometrial carcinoma, if aromatase-inhibitory drugs cause not only estrogen deprivation but also increased antiproliferative actions of DHT. Further analysis is required to clarify the clinical importance of DHT actions in association with the therapeutic efficacy of aromatas ~~~
  8. ...endocrine treatment ~~~
  9. ...endocrine treatment in breast cancer. Journal of Clinical Pathology 61 197–203. (doi:10.1136/jcp.2006.040378) Brenkman AB, de Keizer PL, van den Broek NJ, Jochemsen AG & Burgering BM 2008 Mdm2 induces mono-ubiquitination of FOXO4. PLoS ONE 3 e2819. (doi:10.1371/journal.pone.0002819) Brisken C 2013 P ~~~
  10. ...endocrine treatment ~~~
For checked items